Skip to main content

Table 3 Multivariable Cox regression analysis of KLK12 mRNA expression in relation to patients’ outcome in triple-negative breast cancer

From: Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients

Clinical parameters

OS

DFS

No.a

HR (95% CI)b

p

No.a

HR (95% CI)b

p

Age

  

<  0.001

  

<  0.001

 ≤ 60 years

60

1

 

60

1

 

 > 60 years

54

3.77 (1.93–7.37)

 

52

3.16 (1.72–5.80)

 

Lymph node status

  

0.036

  

0.065

 N0

62

1

 

61

1

 

 N1/N2/N3

52

1.96 (1.05–3.68)

 

51

1.73 (0.97–3.11)

 

Tumor size

  

0.241

  

0.402

 ≤ 20 mm

31

1

 

31

1

 

 > 20 mm

83

1.64 (0.72–3.73)

 

81

1.35 (0.67–2.74)

 

Histological grade

  

0.465

  

0.255

 II

20

1

 

20

1

 

 III

94

1.36 (0.60–3.10)

 

92

1.60 (0.71–3.62)

 

KLK12 mRNAc

  

0.066

  

0.006

 Negative

60

1

 

58

1

 

 Positive

54

1.80 (0.96–3.38)

 

54

2.33 (1.28–4.24)

 
  1. The biological marker KLK12 mRNA was added to the base model of clinical parameters: age, residual tumor mass, and ascites fluid volume. Significant p-values (p ≤ 0.05) are indicated in bold
  2. a Number of patients
  3. bHR Hazard ratio (CI Confidence interval) of multivariable Cox regression analysis;
  4. c Dichotomized into positive and negative expression